Proposal for Everolimus (Novartis; FDA-approved mTOR inhibitor)

Below is a comprehensive evaluation of everolimus as a potential repurposed therapeutic candidate for treating Polycystic Ovary Syndrome (PCOS). The following report examines the candidate from multiple perspectives using current biochemical, cellular, preclinical, and clinical insights drawn from the literature provided.

Overview of Therapeutic Candidate
Everolimus is an orally administered, semi‐synthetic derivative of sirolimus (rapamycin) that belongs to the “rapalog” family of mTOR inhibitors. It was developed through chemical modification of rapamycin, which itself is a macrolide isolated from the soil bacterium Streptomyces hygroscopicus. This chemical derivatization was undertaken to improve upon the natural product’s oral bioavailability, water solubility, and pharmacokinetic/pharmacodynamic characteristics while maintaining its ability to target the mechanistic target of rapamycin complex 1 (mTORC1) selectively (Liu et al., 2016; Thimmanahalli, 2014). As a member of the targeted kinase inhibitor class specifically aimed at modulating intracellular signaling pathways, everolimus exerts its effects by binding intracellularly to FKBP12. The resulting everolimus–FKBP12 complex then interacts with the FKBP12–rapamycin binding (FRB) domain of mTOR, leading to the inhibition of mTORC1 activity. This mode of action has been central to therapies in other disease indications where unchecked cell proliferation, metabolic dysregulation, or abnormal cellular growth are factors. In clinical practice, everolimus has been utilized to prevent organ transplant rejection, as well as in the treatment of several cancers such as renal cell carcinoma and certain neuroendocrine tumors, as well as settings like tuberous sclerosis complex (Liu et al., 2016; Thimmanahalli, 2014). The underlying principle of mTORC1 inhibition – reducing aberrant signals that drive excessive protein synthesis, cell proliferation, and metabolic activity – is especially relevant given that PCOS is characterized by disturbances in ovarian folliculogenesis and insulin signaling.

Therapeutic History
Everolimus has a robust clinical and preclinical history in diverse therapeutic arenas. It has been widely used in the transplantation field as an immunosuppressant to prevent graft rejection. In oncology, its role in inhibiting tumor cell proliferation and angiogenesis is well documented. Its safety and pharmacokinetic profiles have been delineated in multiple clinical trials, demonstrating manageable adverse events such as immunosuppression, hyperlipidemia, and glucose intolerance in patient populations where these side effects are mitigated through careful dosing strategies (Hensley et al., 2020; Liu et al., 2016).

Notably, while everolimus has been approved and extensively evaluated for uses in cancer and transplant medicine, searches specifically for its use in PCOS or related ovarian metabolic dysfunctions via clinical trial registries have yielded zero results (ClinicalTrials.gov, n.d.). However, preclinical investigations and mechanistic studies indicate that the mTOR signaling pathway is dysregulated in PCOS, particularly in ovarian granulosa cells. These cells are central to follicle development and insulin signaling, and dysregulation in mTOR activity can lead to the insulin resistance and follicular arrest characteristic of PCOS (Liu et al., 2016; Bajwa, 2018). Additionally, similar compounds in the rapalog class have been evaluated in contexts that mirror aspects of PCOS pathophysiology, including aberrant folliculogenesis and abnormal ovarian insulin signaling. Hence, despite the absence of direct clinical trial data in PCOS, there is sufficient rationale supporting the exploration of everolimus in this new indication.

Mechanism of Action
At the molecular level, everolimus exerts its activity by selectively inhibiting mTORC1. The process begins with everolimus binding to the immunophilin FKBP12 within the cell. This complex is then able to attach to the FRB domain of mTOR. Under normal circumstances, mTORC1 integrates various upstream signals such as nutrient availability, energy status, growth factors, and stress signals to regulate key downstream effectors. Among these downstream targets are p70 S6 kinase (p70S6K) and the eukaryotic initiation factor 4E-binding protein (4E-BP1). When p70S6K is activated, it phosphorylates ribosomal protein S6, thereby stimulating protein synthesis and promoting cell growth and proliferation (Liu et al., 2016; Thimmanahalli, 2014).

In the ovarian microenvironment, particularly within granulosa cells, controlled mTORC1 activity is essential for proper folliculogenesis and oocyte maturation. These cells rely on mTORC1 signaling for regulated proliferation and differentiation so that follicles can progress normally. In PCOS, there is convincing evidence that hyperactivation of mTORC1 contributes to abnormal granulosa cell proliferation, disrupted follicle maturation, and defective insulin signaling. Specifically, the overactivation of mTORC1 leads to increased activity of p70S6K. This in turn causes serine phosphorylation of insulin receptor substrate 1 (IRS-1), which is a negative feedback mechanism. When IRS-1 is hyperphosphorylated on serine residues, its ability to propagate signals downstream to the PI3K/Akt pathway is substantially impaired, thereby contributing to insulin resistance in the ovary (Liu et al., 2016; Sercombe, n.d.).

Moreover, proper insulin signaling is critical for stimulating the translocation of GLUT4, a glucose transporter, to the plasma membrane, ensuring efficient glucose uptake. In a state of insulin resistance, as observed in PCOS, impaired GLUT4 translocation further exacerbates metabolic dysfunction in ovarian tissues. Everolimus, by inhibiting mTORC1, is proposed to interrupt this detrimental sequence. By counteracting excessive p70S6K activity, it could reduce the aberrant serine phosphorylation of IRS-1, thereby mitigating the negative feedback loop and restoring effective PI3K/Akt signaling. The restoration of proper signaling is expected to facilitate the translocation of GLUT4, ultimately improving insulin sensitivity in granulosa cells (Liu et al., 2016; Sercombe, n.d.).

Preclinical studies provide additional support for this mode of action. In vitro ovarian models and rodent studies that simulate PCOS-like conditions have shown that modulating mTOR activity can lead to normalization of granulosa cell proliferation and improved folliculogenesis. In these models, the use of mTOR inhibitors has resulted in diminished markers of mTOR hyperactivity along with improved cellular responses in the insulin signaling cascade (Sercombe, n.d.; Bajwa, 2018).

Expected Effect
The expectation behind repurposing everolimus in PCOS is centered on its capacity to correct ovarian insulin resistance by normalizing hyperactive mTORC1 signaling in granulosa cells. In PCOS, granulosa cells often exhibit excessively active mTORC1 signaling, leading to the overactivation of p70S6K. This cascade results in increased serine phosphorylation of IRS-1, which dampens the signaling throughput via the PI3K/Akt pathway. The diminished PI3K/Akt activity hampers insulin’s ability to stimulate GLUT4 translocation, thereby reducing glucose uptake and contributing further to insulin resistance (Liu et al., 2016; Sercombe, n.d.).

Upon administration, everolimus is expected to inhibit mTORC1 effectively, thus reducing the activity of p70S6K. With lower p70S6K activity, the inhibitory serine phosphorylation of IRS-1 would decrease. As a consequence, IRS-1 can better engage with PI3K, consequently leading to enhanced activation of Akt. Improved PI3K/Akt signaling would then restore the insulin-mediated translocation of GLUT4 to the cell surface, thereby enhancing cellular glucose uptake and overall insulin sensitivity within the ovarian microenvironment (Liu et al., 2016; Sercombe, n.d.).

In the context of granulosa cell function, the normalization of these signaling pathways should promote proper cell proliferation and differentiation, thereby enabling healthier follicle development. In experimental models, the correction of granulosa cell proliferation through mTOR pathway modulation has been associated with normalized follicular dynamics, decreased cyst formation, and an improvement in markers of ovarian insulin sensitivity. This suggests that everolimus could not only address the metabolic derangements due to insulin resistance but also improve the reproductive outcomes by supporting the maturation of follicles needed for ovulation (Liu et al., 2016; Sercombe, n.d.).

It is important to note that the therapeutic action of everolimus in this setting is expected to be cytostatic rather than cytotoxic. The goal is to moderate the aberrant overproliferation of granulosa cells and restore a more normal cellular state, rather than inducing cell death. This aspect is critical in preserving the ovarian reserve and ensuring that the treatment does not adversely affect overall follicle viability. The desired outcome would be improved folliculogenesis coupled with better insulin sensitivity, which together could alleviate key clinical features of PCOS such as polycystic ovarian morphology, ovulatory dysfunction, and metabolic insufficiency (Liu et al., 2016; Sercombe, n.d.).

Overall, the expected cascade of effects starts with everolimus-mediated inhibition of mTORC1, leading to reduced p70S6K activation, which reinstates normal IRS-1 signaling. The subsequent emergence of effective PI3K/Akt activity promotes proper GLUT4 translocation and insulin sensitivity in ovarian granulosa cells, thereby contributing to a normalization of follicular development and overall metabolic balance in the ovary (Liu et al., 2016; Sercombe, n.d.).

Overall Evaluation
In evaluating everolimus as a repurposed candidate for PCOS, several strengths and challenges emerge based on the available literature.

One of the core strengths is the well-defined mechanism of action of everolimus. Its selective inhibition of mTORC1 is already well documented in oncology and transplant contexts, and the biochemical pathways that it targets are explicitly implicated in PCOS pathology. The hyperactivation of mTORC1 in ovarian granulosa cells, which leads to dysregulated p70S6K activity and subsequent negative feedback on IRS-1, provides a strong mechanistic rationale for the use of everolimus in restoring normal insulin receptor function. With the normalization of IRS-1 signaling, the downstream PI3K/Akt pathway can be reactivated, thereby promoting GLUT4 translocation and improved cellular glucose uptake. This mechanism directly addresses a critical feature of PCOS, namely insulin resistance at the ovarian level (Liu et al., 2016; Sercombe, n.d.).

Additionally, everolimus benefits from an extensive clinical history. Its use in preventing organ rejection and treating various cancers means that there is a tremendous amount of data available on its pharmacokinetics, pharmacodynamics, dosing strategies, and safety profile. Adverse effects such as immunosuppression, hyperlipidemia, and glucose intolerance have been observed, but these are well characterized and can be managed with dose adjustments and patient monitoring (Hensley et al., 2020; Liu et al., 2016; Mahmood et al., 2013). This robust dataset provides confidence that, from a repurposing perspective, everolimus can be rapidly advanced into early-phase clinical trials for PCOS if the preclinical rationale is confirmed.

From a preclinical standpoint, several studies using in vitro ovarian models and rodent experiments demonstrate that modulation of the mTOR signaling pathway can reverse aberrant ovarian phenotypes. For instance, there is evidence that mTOR inhibitors can restore normal granulosa cell proliferation and promote proper folliculogenesis, which are crucial for ovulatory competence (Sercombe, n.d.; Bajwa, 2018). Moreover, the role of mTOR in regulating insulin signaling cascades, including PI3K/Akt and GLUT4 translocation, has been substantiated in multiple studies, lending further support to the hypothesis that everolimus could correct metabolic anomalies in PCOS (Liu et al., 2016).

Notwithstanding these strengths, several challenges must be addressed. A significant drawback is the absence of direct clinical evidence for everolimus in PCOS patients. Currently, there are no registered clinical trials specifically investigating its efficacy in the context of PCOS (ClinicalTrials.gov, n.d.). Much of the supporting data are derived from preclinical models or indirectly from studies conducted in oncology and transplant medicine. Extrapolating these findings to the complex endocrine milieu of PCOS carries inherent risks due to differences in disease pathology, patient demographics, and treatment endpoints (Liu et al., 2016; Sercombe, n.d.).

Furthermore, PCOS is a multifactorial disorder characterized not only by insulin resistance and aberrant folliculogenesis but also by hyperandrogenism, chronic low-grade inflammation, and neuroendocrine dysregulation. While everolimus targets mTORC1 and can theoretically restore proper insulin signaling, it is uncertain how effectively it will modulate the other burgeoning aspects of PCOS pathophysiology. For example, hyperandrogenism has widespread effects throughout the ovary and on systemic metabolic function, and mTOR dysregulation may represent only one facet of this complex network (Sercombe, n.d.).

Additionally, although the cytostatic nature of mTOR inhibitors is beneficial in terms of preventing overproliferation of granulosa cells, there is a risk that excessive inhibition might adversely affect normal ovarian function. Preclinical models have shown that mTOR inhibition, if not properly calibrated, can interfere with normal ovulatory processes, delay pubertal onset, or even contribute to ovarian atrophy. These risks emphasize the necessity for careful dose optimization and appropriate patient selection in any future clinical trial (Liu et al., 2016; Sercombe, n.d.).

Another potential concern centers on the systemic metabolic effects of everolimus. While the goal is to improve ovarian insulin sensitivity, everolimus is also known to induce hyperglycemia and dyslipidemia in other patient populations. It is crucial to determine whether these adverse effects will be offset by the improvements in local ovarian insulin signaling or whether they might worsen the metabolic profile of patients with PCOS, who already have a predisposition to metabolic syndrome (Liu et al., 2016; Mahmood et al., 2013).

In summary, everolimus offers a compelling and scientifically rational candidate for repurposing in PCOS due to its selective inhibition of mTORC1, a key driver of the insulin signaling abnormalities and follicular dysfunction observed in this syndrome. Its mechanism—reducing p70S6K-mediated inhibitory phosphorylation of IRS-1 to restore PI3K/Akt/GLUT4 signaling—addresses a fundamental defect in PCOS pathophysiology. The extensive clinical experience with everolimus in other settings provides a strong basis for safety and pharmacological predictability. However, the lack of direct clinical data in PCOS, potential risks related to off-target systemic effects, and the multifactorial nature of PCOS remain significant challenges that must be addressed through careful preclinical optimization and eventual clinical trials.

Moving forward, targeted preclinical studies should focus on evaluating everolimus in robust in vitro ovarian models and relevant rodent models of PCOS. These studies should assess not only improvements in insulin signaling and GLUT4 translocation in granulosa cells but also the broader impact on folliculogenesis and systemic metabolic parameters. Should these studies yield promising results, they would justify early-phase clinical trials in carefully selected PCOS populations with the aim of determining the therapeutic window, dosing regimen, and potential biomarkers of response. The overall promise of everolimus as a novel intervention for PCOS thus rests on its ability to rebalance ovarian insulin signaling and restore normal follicular dynamics while managing the inherent risks associated with mTOR inhibition (Liu et al., 2016; Sercombe, n.d.; ClinicalTrials.gov, n.d.; Hensley et al., 2020).

Overall, despite the challenges highlighted, everolimus represents a promising and rational candidate for repurposing in the treatment of PCOS. Its established mechanism, well-characterized clinical profile, and supportive preclinical evidence provide a strong foundation—if future targeted studies can confirm paracrine and systemic benefits without undue side effects. Given the substantial unmet need in PCOS treatment, particularly in addressing the metabolic and reproductive dysfunctions that drive patient morbidity, everolimus bears significant translational potential that merits further investigation.

References:
Bajwa, P. (2018). Age-related mTOR in ovarian and endometrial cancers. [Unknown journal].

ClinicalTrials.gov. (n.d.). Search for Everolimus AND (Polycystic Ovary Syndrome OR PCOS OR ovarian insulin resistance OR mTOR inhibitor ovary). Retrieved from https://clinicaltrials.gov

Hensley, M., Pautier, P., & Friedlander, M. (2020). Management of Endometrial Cancer. Springer International Publishing. https://doi.org/10.1007/978-3-319-64513-1

Liu, A., Liao, H., Li, Z. L., Liu, J., Zhou, C., Guo, Z., Xie, H., & Peng, C. (2016). New insights into mTOR signal pathways in ovarian-related diseases: Polycystic ovary syndrome and ovarian cancer. Asian Pacific Journal of Cancer Prevention, 17, 5087–5094. https://doi.org/10.22034/apjcp.2016.17.12.5087

Mahmood, K., Naeem, M., & Rahimnajjad, N. A. (2013). Metformin: The hidden chronicles of a magic drug. European Journal of Internal Medicine, 24, 20–26. https://doi.org/10.1016/j.ejim.2012.10.011

Sercombe, L. (n.d.). Understanding the role of the mTOR signalling pathway in the ovary during folliculogenesis, PCOS and hyperandrogenism. [Unknown journal].

Thimmanahalli, D. S. (2014). Mechanistic target of rapamycin and extracellular signal regulated kinase 1/2 signaling in ovarian granulosa cells. [Unknown journal].
